CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Aadi Bioscience (AADI) surges 12% on first-ever approval

By Robert Davis

21:11, 23 November 2021

Scientist using a pipette at a biomedical laboratory
. Photo: Shutterstock

Aadi Bioscience (AADI) stock surged 12% during pre-market hours on Tuesday to $32.20 after the US Food and Drug Administration (FDA) approved a drug that treats a rare form of cancer.

By the closing bell Tuesday, Aadi’s stock had sank to $24.32 per share, representing a 4.7% drop from its close price of $25.52 on Monday.

Fyarro was developed by Aadi to treat unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). It is the first and only FDA-approved treatment for this cancer.

Dr. Neil Desai, founder and CEO of Aadi, called the approval a “momentous event” both for the patients who need the treatment and their caretakers.

Standard of care

Other doctors described Fyarro’s approval as a new weapon for treating patients who received a poor prognosis and have limited treatment options.


0.68 Price
+3.980% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030


16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0


44,241.20 Price
+1.790% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Andrew Wagner, a senior oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, said in a statement that the drug will be “welcomed by the physician community” because of its effectiveness at treating advanced forms of the cancer.

According to Fyarro’s Phase 2 results, the drug generated an overall response rate of 39% in patients with advanced PEComa.

Of the responders, more than 92% went into remission for at least six months. Two-thirds were in remission for at least one year, and 58% were in remission for two years.

Brendan Delaney, chief operating officer of Aadi, said the results could make Fyarro the “standard of care” for this cancer.

Read more: AstraZeneca buys rare disease drugmaker Caelum in 0m deal

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading